Use of GnRH Agonist for Luteal Support in Women Undergoing IVF, ICSI, or Frozen Embryo Transfer Cycles

What this Trial Is About

This research evaluates the use of a single administration of a GnRH agonist for additional support during the luteal phase in women undergoing IVF, ICSI, or frozen embryo transfer FET cycles. The study aims to improve embryo implantation and live birth rates by enhancing the hormonal environment between the embryo and endometrium. It is a Phase 4 randomized trial assessing treatment effectiveness in infertility. Participants are randomly assigned to receive either a single shot of GnRH agonist or a placebo around the time of embryo transfer. All participants are women under the age of 40 undergoing IVF, ICSI, or FET cycles. The trial compares these two groups to evaluate the impact on implantation and pregnancy outcomes. During the study, participants will be monitored for live birth outcomes over nine months following embryo transfer. Secondary outcomes include implantation rates, clinical pregnancy rates, and rates of ovarian hyperstimulation syndrome OHSS assessed at four weeks. The study uses quadruple masking to ensure unbiased results and includes safety and efficacy assessments throughout the trial period.

GnRH for Luteal Support in IVF/ICSI/FET Cycles